• Follow us
  • Holding BUMN Farmasi
  • For Healthcare Professional
  • Researcher
  • EN
    Flag IndonesiaID
    Flag EnglishEN
biofarma-logo-bumn biofarma-logo biofarma-logo-131 biofarma-logo-hashtag-only-case
  • Home
  • Who We Are

    About Us
    • Our Focus
    • Our Strategy
    • Our Distribution
    • Our Operations
    • Your Career
    Our Leadership
    • Corporate Executive Team
    • Management Team
    Our Achievement
    • Awards
    • Certification
    Sustainability
    • Our People
    • Access to Vaccine
    • Corporate Social Responsibility
    • Good Corporate Governance
    • Biodiversity
  • Product & Service

    Our Product
    • Combination Vaccine
    • Viral Vaccine
    • Bacterial Vaccine
    • Diagnostic Vaccine
    • Sera
    Our Health Service
    • Service of Industrial Micro Biology
    • Clinical Laboratory Service
    • Vaccination Service
    • Clinic & Pharmacy

    Visit our website

  • Media

    For Media
    • Latest News
    • Current Event
    Vaccine Fact
    Media Release
    FAQ
  • I Want to
search

Bio Farma to Explore Immunotherapy Products for Cancer

Monday, 16 December 2019

 

(Jakarta 16/12) Bio Farma has expanded collaboration with two South Korean companie: ForeverNK Inc. and Aribio Co. Ltd. The beginning of this collaboration was signed in  Memorandum of Understanding (MoU) between Bio Farma and two companies based in Seongnam, regarding the exploration and development of potential business opportunities for therapeutic products for cancer treatment.

The products use "NK Cell Therapy" technology will be provided by ForeverNK Inc, meanwhile "NK Cell Conditioned Media" will be obtained from Aribio Co. Ltd.

NK (Natural Killer) Cells are innate lymphoid cells that provide early protection against cancer development by killing abnormal cells in the body that undergo cellular transformation without the need for prior stimulation. NK Cell therapy technology, will be provided by ForeverNK. Meanwhile, NK Cell Conditioned Media is a medium or 'place' for the growth of NK Cells to be made in a tissue culture made by Aribio.

This MoU was signed by the President Director of Bio Farma, Honesti Basyir, Chief Executive Officer ForeverNK, Jung Hoon Oh, and Vice Chariman, Soo-Hyun Sung, on December 16, 2019 in Jakarta.

In his spech, Honesti Basyir said, as state-owned pharmaceutical holding company (per last October 2019) Bio Farma will expand into the pharmaceutical product business especialy in immunotherapy , as the result this MoU.  “This collaboration is the beginning of the initiation of Bio Farma products for immunotherapy, especially for cancer.

As a first step together with two South Korean companies will develop and evaluate market potential opportunities, and set terms and conditions for evaluations related to NK Cell Therapy from ForeverNK and cosmetic products including NK Cell Conditioned Media from ARIBIO. ", said Honesti.

Honesti added, immunotherapy is a type of treatment that encourages our body's own immune system, to be more effective in fighting diseases, including cancer. Bio Farma will play a role in examining and evaluating technologies and products to use them in Indonesia, collabore with hospitals, applying for licenses, and then being marketed in Indonesia through clinical services.

Meanwhile, Fred Kim, representative of Aribio US, said that his party very welcomes to sign this MoU, because Bio Farma and ForeverNK have same philosophy, to dedicate this product for improve teh quality of live and through this give benefit to many people. We hope with this collaboration, will create a product that can be useful for a better life," said Fred. (ed/ss)

  • Share to:
Download

Latest News

PIALA BMGF
Thursday, 19 May 2022
Bio Farma Receives Appreciation from the Bill and Melinda Gates Foundation
BIO FARMA MDI
Wednesday, 11 May 2022
Building Bio-Health Fund, Bio Farma Together with MDI Invest to Targeting Opportunities in Health Sector Startups
Ilustrasi produksi BF
Thursday, 24 February 2022
Bio Farma to Receive mRNA Vaccine Transfer Technology
View more

Head Office
Jl. Pasteur No. 28, Bandung 40161,
Jawa Barat Indonesia
No. Telp
+62 22-2033755
Fax
+62 22 - 2041306
Bio Care
1500810
Email
mail@biofarma.co.id
website
www.biofarma.co.id
Digital Healthcare Office Jakarta Lt. 26
Equity Tower Sudirman Central Business District (SCBD) Lot 9
Jl. Jend. Sudirman Kav. 52-53
Jakarta Selatan 12190, Indonesia
Information
  • Good Corporate Governance
  • Our Procurement
  • FAQ
  • Vaccine Production
  • Your Career
 
  • Contact Us
  • E-PPID
  • Announcement
  • I Want to
  • Media Release
Our Partner

Quick Links
  • Portal BUMN-Bio
  • Kemenkes RI
Copyright © 2022. All Rights Reserved by Bio Farma
Holding BUMN Farmasi
For Healthcare Professional
Researcher

Change Language

EN
  • Home
  • Who We Are
    • About Us
      • About Us
      • Our Focus
      • Our Strategy
      • Our Distribution
      • Our Operations
      • Your Career
    • Our Leadership
      • Corporate Executive Team
      • Management Team
    • Our Achievement
      • Awards
      • Certification
    • Sustainability
      • Our People
      • Access to Vaccine
      • Corporate Social Responsibility
      • Good Corporate Governance
      • Biodiversity
  • Product & Service
    • Our Product
      • Our Product
      • Combination Vaccine
      • Viral Vaccine
      • Bacterial Vaccine
      • Diagnostic Vaccine
      • Sera
    • Our Health Service
      • Our Health Service
      • Service of Industrial Micro Biology
      • Clinical Laboratory Service
      • Vaccination Service
      • Clinic & Pharmacy
  • Media
    • For Media
      • For Media
      • Latest News
      • Current Event
    • Vaccine Fact
    • Media Release
    • FAQ
  • I Want to
  • Follow us
Change Language
  • Flag IndonesiaID
  • Flag EnglishEN
BIO CARE 1500810 icon-phone
Youtube icon-youtube
Corporate Reporting icon-statistics